May 18, 2017 / 1:29 PM / 3 months ago

BRIEF-Amgen submits Biologics License Application to the FDA for erenumab

May 18 (Reuters) - Amgen Inc

* Amgen submits biologics license application to the fda for erenumab

* Amgen inc says bla includes data from pivotal studies in patients with episodic and chronic migraine

* Amgen inc - announced submission of a biologics license application to u.s. Food and drug administration for erenumab to prevent migraine Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below